Treating a Rare Cancer with a Chemotherapy Gel
The FDA has approved a chemotherapy gel for treating certain patients with cancer of the upper urinary tract. he...
Progress Against Cancer
The FDA has approved a chemotherapy gel for treating certain patients with cancer of the upper urinary tract. he...
The FDA has approved a molecularly targeted therapeutic for treating certain patients with neurofibromatosis type 1 who have inoperable...
The FDA has approved a new combination of molecularly targeted therapeutics for treating metastatic colorectal cancer with a BRAF...
The FDA has approved a new combination of immunotherapy and chemotherapy as an initial treatment for extensive-stage small cell...
The FDA approved using a combination of nivolumab and ipilimumab, two immune checkpoint inhibitors, to treat certain patients with...
The FDA has approved the immunotherapeutic isatuximab-irfc (Sarclisa) to treat certain patients with multiple myeloma. The U.S. Food and...
The FDA has expanded the use of the molecularly targeted therapeutic neratinib to include the treatment of certain patients...
The FDA has approved a targeted therapy for epithelioid sarcoma, the first treatment approved for this form of cancer....
The FDA has approved a molecularly targeted treatment for certain patients with this form of soft tissue sarcoma. The...
The FDA approved the use of the targeted therapeutic olaparib to treat certain pancreatic cancer patients whose disease has...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 47,000 members worldwide drive progress against cancer.
Donate Today